Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

In a significant move to address supply constraints, Eli Lilly announced a $6 billion investment to construct a new manufacturing facility in Huntsville, Alabama. This site is slated to produce both ...

In the latest close session, Eli Lilly (LLY) was up +2.44% at $839.87. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow gained 0.51%, while the ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

This week, Eli Lilly secured a significant regulatory victory. The U.S. Food and Drug Administration (FDA) granted full, traditional approval for the cancer drug Jaypirca. This upgrades its status ...

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 23 unusual trades. Delving into the details, we found 47% of ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

In November 2025, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology firm specializing in therapies for primary ...

Pharmaceutical giant Eli Lilly has teamed up with Breakthrough Properties to build out a new incubator lab space in Center City. The 44K SF Lilly Gateway Labs at Breakthrough will feature ...